This clinical case-based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined. The discussion covers the main aspects of the management of metastatic RCC, such as the role of cytoreductive nephrectomy and metastasis-directed therapies, as well as the multiple options for systemic targeted and immune therapies. An insight into developments that may play a role in treatment pathways in the future according to the latest scientific advances is also provided. PATIENT SUMMARY: A number of treatment options are available for patients who have metastatic disease when diagnosed with clear-cell kidney cancer. Starting from a clinical case, the current standard of care and future perspectives regarding treatment of this disease are presented.
European urology oncology. 2021 Sep 13 [Epub ahead of print]
Daniel Benamran, Laurence Albiges, Axel Bex, Gianluca Giannarini, Umberto Capitanio, Morgan Rouprêt, European Association of Urology Section of Oncological Urology Board
Division of Urology, Geneva University Hospitals, Geneva, Switzerland., Department of Medical Oncology, Gustave Roussy, Villejuif, France., Department of Urology, Netherlands Cancer Institute, Amsterdam, Netherlands., Urology Unit, Santa Maria della Misericordia University Hospital, Udine, Italy., Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, F-75013 Paris, France. Electronic address: .